Topics

Articles

Pharma Commerce travels to Orlando for a pulse-check on this fast-evolving landscape in patient care.  

Access Insights and Information Abound

And the need to boost awareness of this critical healthcare resource.

A Look at the Medicare 'Extra Help' Program

An analysis of the two main new models for pharmacy—unique direct—to-consumer for brands and cash pay for generics—and what members of industry think about them.

Who Moved My Prescription? Part II

An analysis conducted by RAND Corporation determines that majority of new Rx medications are first sold in the United States before making their debut in other countries. 

A Comparison of Prescription Drug Availability 

A dive into this market reveals that the latest numbers yield promising results—a global value of a worldwide $1.6 trillion—but it will continue to be attributed to past, present, and future healthcare spending. 

The Path for Prescription Drug Sales 

Health Affairs study investigates the consequences of patient medication abandonment surrounding oral HIV pre-exposure prophylaxis.

Forecasting the Effect of Out-of-Pocket Cost Changes for HIV Medication

In order to provide both profitability and medication access, a balancing act is required.

A Pharma Pricing and Agreements Primer in Today's Complex Landscape

Duplicate rebates have resulted in revenue leakage for manufacturers.

The Impact of 340B on Commercial Contracts

New England Journal of Medicine study provides a breakdown of how hospitals—especially those that qualify for discounts under the federal 340B Drug Pricing Program—are able to make a profit off insurer pharmaceutical expenditures. 

A Behind-the-Scenes Look at Drug Price Markups 

In an interview with Pharma Commerce Associate Editor Don Tracy, Ron Lanton, Partner, Lanton Law PLLC, discusses recent moves by CVS and Express Scripts to follow Mark Cuban's drug plus model.

Market Access